Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09RVI
|
|||
| Former ID |
DCL001245
|
|||
| Drug Name |
Tegobuvir
|
|||
| Synonyms |
Tegobuvir; 1000787-75-6; UNII-5NOK5X389M; 5-((6-(2,4-bis(Trifluoromethyl)phenyl)pyridazin-3-yl)methyl)-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine; 5NOK5X389M; GS-9190; GS-333126; W-204340; 5H-Imidazo[4,5-c]pyridine, 5-[[6-[2,4-bis(trifluoromethyl)phenyl]-3-pyridazinyl]methyl]-2-(2-fluorophenyl)-;5H-Imidazo[4,5-c]pyridine, 5-[[6-[2,4-bis(trifluoromethyl)phenyl]-3-pyridazinyl]methyl]-2-(2-fluorophenyl)-; Tegobuvir [USAN:INN]; GS 9190; Tegobuvir (USAN/INN); GS 333126; SCHEMBL496778; CHEMBL1957287; DTXSID80142917
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hepatitis C virus infection [ICD-11: 1E51.1; ICD-10: B18.2] | Phase 2 | [1] | |
| Company |
Gilead
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H14F7N5
|
|||
| Canonical SMILES |
C1=CC=C(C(=C1)C2=NC3=CN(C=CC3=N2)CC4=NN=C(C=C4)C5=C(C=C(C=C5)C(F)(F)F)C(F)(F)F)F
|
|||
| InChI |
1S/C25H14F7N5/c26-19-4-2-1-3-17(19)23-33-21-9-10-37(13-22(21)34-23)12-15-6-8-20(36-35-15)16-7-5-14(24(27,28)29)11-18(16)25(30,31)32/h1-11,13H,12H2
|
|||
| InChIKey |
XBEQSQDCBSKCHJ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1000787-75-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) | Target Info | Inhibitor | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Gilead (2011). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.